{"schema_version":"secwatch.filing_event.v1","accession":"0000896622-24-000038","form_type":"8-K","ticker":"ATR","cik":"0000896622","company_name":"APTARGROUP, INC.","filed_at":"2024-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.320891+00:00","generated_at":"2026-05-30T10:50:25.974375+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aptar reports Q3 net income $100M (+19%), adjusted EPS $1.49 (+6%)","bullets":["Revenue $909M (+2% core sales); Pharma segment core sales +7%, Beauty -6%, Closures +4%.","Adjusted EBITDA $208M (23% margin); reported EPS $1.48 vs $1.26 prior year.","Q4 2024 adjusted EPS guidance $1.22-$1.30; full year adjusted EPS outlook $5.34-$5.42, double-digit YoY growth.","Quarterly dividend $0.45/share, payable Nov 14 to holders of record Oct 24; Board authorized $500M share repurchase program.","Pharma drug delivery systems grew double digits; Closures margins up ~200 bps YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0000896622-24-000038","json":"https://secwatch.observer/filing/0000896622-24-000038.json","markdown":"https://secwatch.observer/filing/0000896622-24-000038.md","text":"https://secwatch.observer/filing/0000896622-24-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896622/000089662224000038/0000896622-24-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896622/000089662224000038/atr-20241024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:50:25.974375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}